{"transactions":[{"id":4500,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-09-04T20:22:41.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":5124,"price":3.0372,"value":15562.6128,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":243189,"source":{"system":"sec-edgar","filing":"0001742084-26-000003","document":"wk-form4_1788553359.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742084/000174208426000003/wk-form4_1788553359.xml","form_type":"4"}},{"id":747455,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-06-05T20:33:02.000Z","date":"2026-06-03","kind":"sale","planned":true,"acquired":false,"shares":15380,"price":2.7011,"value":41542.918,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax\nwithholding obligations as a result of vesting in restricted stock units on June 2, 2026. The sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $2.7010 to $2.7250. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":248313,"source":{"system":"sec-edgar","filing":"0001650664-26-000056","document":"wk-form4_1780691579.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000056/wk-form4_1780691579.xml","form_type":"4"}},{"id":841089,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to  buy)","published_at":"2026-03-16T20:37:09.000Z","date":"2026-03-12","kind":"grant","planned":true,"acquired":true,"shares":1015200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 12, 2026 and is scheduled to vest over four years in equal monthly installments beginning on April 12, 2026 through March 12, 2030."}],"balance_after":1015200,"derivative":{"exercise_price":2.54,"expiration_date":"2036-03-11","underlying":"Common Stock","underlying_shares":1015200},"source":{"system":"sec-edgar","filing":"0001650664-26-000023","document":"wk-form4_1773693426.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000023/wk-form4_1773693426.xml","form_type":"4"}},{"id":860636,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-03-04T21:56:01.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":5394,"price":2.0197,"value":10894.2618,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2026. The sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $2.0050 to $2.0204 The price reported above reflects the weighted average purchase price. The Reporting Person hereby\nundertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":263693,"source":{"system":"sec-edgar","filing":"0001650664-26-000009","document":"wk-form4_1772661358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000009/wk-form4_1772661358.xml","form_type":"4"}},{"id":979973,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-12-04T21:38:41.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":5603,"price":2.1531,"value":12063.8193,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax\nwithholding obligations as a result of vesting in restricted stock units on December 2, 2025. The sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":269087,"source":{"system":"sec-edgar","filing":"0001650664-25-000162","document":"wk-form4_1764884318.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000162/wk-form4_1764884318.xml","form_type":"4"}},{"id":1047511,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-09-04T20:20:00.000Z","date":"2025-09-03","kind":"sale","planned":true,"acquired":false,"shares":5592,"price":2.5961,"value":14517.3912,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2025. The sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":274690,"source":{"system":"sec-edgar","filing":"0001650664-25-000141","document":"wk-form4_1757017197.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000141/wk-form4_1757017197.xml","form_type":"4"}},{"id":1122360,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-06-04T22:36:39.000Z","date":"2025-06-03","kind":"sale","planned":true,"acquired":false,"shares":15192,"price":1.7243,"value":26195.5656,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2025. The sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $1.7239 to $1.7566 . The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":280282,"source":{"system":"sec-edgar","filing":"0001650664-25-000089","document":"wk-form4_1749076593.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000089/wk-form4_1749076593.xml","form_type":"4"}},{"id":1189487,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to  buy)","published_at":"2025-03-27T20:37:39.000Z","date":"2025-03-08","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 8, 2025 and is scheduled to vest in full on September 8, 2026."}],"balance_after":175000,"derivative":{"exercise_price":1.72,"expiration_date":"2035-03-07","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001650664-25-000037","document":"wk-form4_1743107853.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000037/wk-form4_1743107853.xml","form_type":"4"}},{"id":1189486,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to  buy)","published_at":"2025-03-27T20:37:39.000Z","date":"2025-03-08","kind":"grant","planned":false,"acquired":true,"shares":828000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 8, 2025 and is scheduled to vest over four years in equal monthly installments beginning on April 8, 2025 through March 8, 2029."}],"balance_after":828000,"derivative":{"exercise_price":1.72,"expiration_date":"2035-03-07","underlying":"Common Stock","underlying_shares":828000},"source":{"system":"sec-edgar","filing":"0001650664-25-000037","document":"wk-form4_1743107853.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000037/wk-form4_1743107853.xml","form_type":"4"}},{"id":1221566,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-03-05T21:43:12.000Z","date":"2025-03-04","kind":"sale","planned":true,"acquired":false,"shares":16632,"price":1.7107,"value":28452.3624,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 3, 2025. The sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $1.7107 to $1.7125 . The price reported above reflects the weighted average purchase price. The Reporting Person hereby\nundertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":295474,"source":{"system":"sec-edgar","filing":"0001650664-25-000026","document":"wk-form4_1741210979.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000026/wk-form4_1741210979.xml","form_type":"4"}},{"id":1341293,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-12-05T21:40:31.000Z","date":"2024-12-03","kind":"sale","planned":true,"acquired":false,"shares":1618,"price":2.0774,"value":3361.2332,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December  2, 2024. The sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $2.0550 to $2.0783. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":312106,"source":{"system":"sec-edgar","filing":"0001650664-24-000126","document":"wk-form4_1733434825.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000126/wk-form4_1733434825.xml","form_type":"4"}},{"id":1412508,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-09-06T20:18:20.000Z","date":"2024-09-04","kind":"sale","planned":true,"acquired":false,"shares":1555,"price":3.4247,"value":5325.4085,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2024. The sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $3.4246 to $3.4503. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":313724,"source":{"system":"sec-edgar","filing":"0001650664-24-000103","document":"wk-form4_1725653893.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000103/wk-form4_1725653893.xml","form_type":"4"}},{"id":1471956,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-21T16:30:04.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 21, 2024 or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":1.38,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000950170-24-076285","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017024076285/ownership.xml","form_type":"4"}},{"id":1488032,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-06-06T20:17:11.000Z","date":"2024-06-04","kind":"sale","planned":true,"acquired":false,"shares":12191,"price":5.4956,"value":66996.8596,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2024. The sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":315279,"source":{"system":"sec-edgar","filing":"0001650664-24-000076","document":"wk-form4_1717705020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000076/wk-form4_1717705020.xml","form_type":"4"}},{"id":1593954,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to  buy)","published_at":"2024-03-06T01:00:16.000Z","date":"2024-03-02","kind":"grant","planned":true,"acquired":true,"shares":392100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on March 2, 2024 and is scheduled to vest over four years in equal monthly installments beginning on  April 2, 2024 through March 2, 2028."}],"balance_after":392100,"derivative":{"exercise_price":10.53,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":392100},"source":{"system":"sec-edgar","filing":"0001650664-24-000015","document":"wk-form4_1709686792.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000015/wk-form4_1709686792.xml","form_type":"4"}},{"id":1593953,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-03-06T01:00:16.000Z","date":"2024-03-05","kind":"sale","planned":true,"acquired":false,"shares":77824,"price":9.4172,"value":732884.1728,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2024. The sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $9.1036 to $9.4298. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":327470,"source":{"system":"sec-edgar","filing":"0001650664-24-000015","document":"wk-form4_1709686792.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000015/wk-form4_1709686792.xml","form_type":"4"}},{"id":1593952,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-03-06T01:00:16.000Z","date":"2024-03-02","kind":"grant","planned":true,"acquired":true,"shares":72212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Reflects the vesting, upon the achievement of a business development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 2, 2022."}],"balance_after":405294,"source":{"system":"sec-edgar","filing":"0001650664-24-000015","document":"wk-form4_1709686792.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000015/wk-form4_1709686792.xml","form_type":"4"}},{"id":1593951,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-03-06T01:00:16.000Z","date":"2024-03-02","kind":"grant","planned":true,"acquired":true,"shares":72213,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the vesting, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 2, 2022."}],"balance_after":333082,"source":{"system":"sec-edgar","filing":"0001650664-24-000015","document":"wk-form4_1709686792.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000015/wk-form4_1709686792.xml","form_type":"4"}},{"id":1593950,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-03-06T01:00:16.000Z","date":"2024-03-02","kind":"grant","planned":true,"acquired":true,"shares":130700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2025 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2028."}],"balance_after":260869,"source":{"system":"sec-edgar","filing":"0001650664-24-000015","document":"wk-form4_1709686792.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000015/wk-form4_1709686792.xml","form_type":"4"}},{"id":1844159,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T17:12:02.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 23, 2023 or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":3.25,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000899243-23-016504","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924323016504/doc4.xml","form_type":"4"}},{"id":1863458,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-06-07T20:30:21.000Z","date":"2023-06-05","kind":"sale","planned":true,"acquired":false,"shares":6486,"price":9.5032,"value":61637.7552,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2023. The sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $9.4600 to $9.5034. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":130169,"source":{"system":"sec-edgar","filing":"0001415889-23-009369","document":"form4-06072023_040605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000141588923009369/form4-06072023_040605.xml","form_type":"4"}},{"id":1968194,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-06T21:30:11.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027."}],"balance_after":150000,"derivative":{"exercise_price":8.72,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001415889-23-004313","document":"form4-03062023_040304.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000141588923004313/form4-03062023_040304.xml","form_type":"4"}},{"id":1968193,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-03-06T21:30:11.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2024 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter\nthrough March 2, 2027."}],"balance_after":136655,"source":{"system":"sec-edgar","filing":"0001415889-23-004313","document":"form4-03062023_040304.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000141588923004313/form4-03062023_040304.xml","form_type":"4"}},{"id":2221105,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-27T18:10:03.000Z","date":"2022-06-24","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 24, 2022 or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":0.59,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-22-024228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924322024228/doc4.xml","form_type":"4"}},{"id":2241232,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-06-06T20:44:26.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":950209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 2, 2022 and is scheduled to vest over four years, with 25% of the shares scheduled to vest on June 2, 2023 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through June 2, 2026."}],"balance_after":950209,"derivative":{"exercise_price":11.54,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":950209},"source":{"system":"sec-edgar","filing":"0001415889-22-006159","document":"form4-06062022_010612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000141588922006159/form4-06062022_010612.xml","form_type":"4"}},{"id":2241231,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-06-06T20:44:26.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":86655,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on June 2, 2023 continuing through June 2, 2026."}],"balance_after":86655,"source":{"system":"sec-edgar","filing":"0001415889-22-006159","document":"form4-06062022_010612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000141588922006159/form4-06062022_010612.xml","form_type":"4"}},{"id":2251437,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T16:32:02.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This options vests in ratable monthly installments over one year from the date of grant."}],"balance_after":40000,"derivative":{"exercise_price":0.5,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-22-005911","document":"form4-05312022_040536.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000141588922005911/form4-05312022_040536.xml","form_type":"4"}},{"id":2536371,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-22T16:19:13.000Z","date":"2021-10-19","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests over a three-year period with one-third of the option vesting on the first anniversary of the date of grant and the remaining two-thirds vesting in ratable monthly installments thereafter"}],"balance_after":80000,"derivative":{"exercise_price":2.26,"expiration_date":"2031-10-18","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001415889-21-004946","document":"form4-10222021_011005.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000141588921004946/form4-10222021_011005.xml","form_type":"4"}},{"id":2653396,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-28T17:26:17.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":13425,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 24, 2021 or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date."}],"balance_after":13425,"derivative":{"exercise_price":4.18,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":13425},"source":{"system":"sec-edgar","filing":"0000899243-21-026244","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924321026244/doc4.xml","form_type":"4"}},{"id":2798051,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & CMO"}}],"security":"Common Stock","published_at":"2021-03-11T01:02:42.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On March 5, 2021, the Form 4 filed for the reporting person overstated the number of shares held by the reporting person. This amended form corrects such error by reporting the number of shares withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units on February 28, 2021 and by reporting the corrected total amount of securities directly owned by the reporting person following a grant of restricted stock units on March 3, 2021."}],"balance_after":28546,"source":{"system":"sec-edgar","filing":"0001209191-21-019668","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919121019668/doc4a.xml","form_type":"4/A","original_submission_date":"2021-03-05"}},{"id":2798050,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & CMO"}}],"security":"Common Stock","published_at":"2021-03-11T01:02:42.000Z","date":"2021-02-28","kind":"tax_withholding","acquired":false,"shares":524,"price":86.97,"value":45572.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On March 5, 2021, the Form 4 filed for the reporting person overstated the number of shares held by the reporting person. This amended form corrects such error by reporting the number of shares withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units on February 28, 2021 and by reporting the corrected total amount of securities directly owned by the reporting person following a grant of restricted stock units on March 3, 2021."}],"balance_after":13546,"source":{"system":"sec-edgar","filing":"0001209191-21-019668","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919121019668/doc4a.xml","form_type":"4/A","original_submission_date":"2021-03-05"}},{"id":2807363,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & CMO"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-06T01:05:16.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter."}],"balance_after":60000,"derivative":{"exercise_price":87.11,"exercise_date":"2022-03-03","expiration_date":"2031-03-03","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-21-018420","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919121018420/doc4.xml","form_type":"4"}},{"id":2807362,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & CMO"}}],"security":"Common Stock","published_at":"2021-03-06T01:05:16.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date."}],"balance_after":29070,"source":{"system":"sec-edgar","filing":"0001209191-21-018420","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919121018420/doc4.xml","form_type":"4"}},{"id":2946504,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-14T17:16:11.000Z","date":"2020-12-10","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 36-month period commencing on December 10, 2020 (the \"Vesting Commencement Date\"), so that 100% of the shares become fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":50000,"derivative":{"exercise_price":6.12,"expiration_date":"2030-12-09","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-20-033757","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924320033757/doc4.xml","form_type":"4"}},{"id":3242223,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & CMO"}}],"security":"Stock option (right to buy)","published_at":"2020-02-29T01:02:11.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and\nbecome exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of\nthe date of grant."}],"balance_after":37500,"derivative":{"exercise_price":114.47,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-20-014228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919120014228/doc4.xml","form_type":"4"}},{"id":3242222,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & CMO"}}],"security":"Common Stock","published_at":"2020-02-29T01:02:11.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":6700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. 25% of\nthe shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25%\nwill vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the\nfourth anniversary of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. 25% of\nthe shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25%\nwill vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the\nfourth anniversary of the grant date."}],"balance_after":14070,"source":{"system":"sec-edgar","filing":"0001209191-20-014228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919120014228/doc4.xml","form_type":"4"}},{"id":3512618,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & CMO"}}],"security":"Restricted Stock Units","published_at":"2019-05-25T00:07:06.000Z","date":"2019-05-23","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Sarepta Therapeutics, Inc. common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units have vested on May 23, 2019."}],"balance_after":0,"derivative":{"exercise_date":"2019-05-23","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-19-032835","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119032835/doc4.xml","form_type":"4"}},{"id":3512617,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & CMO"}}],"security":"Common Stock","published_at":"2019-05-25T00:07:06.000Z","date":"2019-05-24","kind":"tax_withholding","acquired":false,"shares":4630,"price":119.31,"value":552405.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Shares were sold by Sarepta Therapeutics, Inc. to satisfy tax obligations related to the vesting of restricted stock units."}],"balance_after":7370,"source":{"system":"sec-edgar","filing":"0001209191-19-032835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119032835/doc4.xml","form_type":"4"}},{"id":3512616,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & CMO"}}],"security":"Common Stock","published_at":"2019-05-25T00:07:06.000Z","date":"2019-05-23","kind":"exercise","acquired":true,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Sarepta Therapeutics, Inc. common stock."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001209191-19-032835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119032835/doc4.xml","form_type":"4"}},{"id":3620940,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & CMO"}}],"security":"Stock option (right to buy)","published_at":"2019-03-05T01:09:44.000Z","date":"2019-03-04","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant."}],"balance_after":55000,"derivative":{"exercise_price":145.48,"expiration_date":"2029-03-04","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-19-016044","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119016044/doc4.xml","form_type":"4"}},{"id":3899197,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2018-06-11T22:11:06.000Z","date":"2018-06-07","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Sarepta Therapeutics, Inc. common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units will vest on May 23, 2019."}],"balance_after":12000,"derivative":{"exercise_date":"2019-05-23","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-18-037075","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118037075/doc4.xml","form_type":"4"}},{"id":3899196,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":10088,"kind":"person","name":"O'Neill Gilmore Neil","position":1,"cik":"0001742084","reported_name":"O'Neill Gilmore Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-11T22:11:06.000Z","date":"2018-06-07","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant."}],"balance_after":100000,"derivative":{"exercise_price":96.23,"expiration_date":"2028-06-07","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-18-037075","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118037075/doc4.xml","form_type":"4"}}]}